June 3, 2015 -
PRLog -- The Oncology Institute of Hope and Innovation is proud to have access to the latest research, technology and treatment options, including clinical trials for eligible patients. We are dedicated to providing comprehensive medical services to our patients. In our quest to be at the forefront of the latest medical cancer research, we participate in numerous clinical trials focused on various types of malignancies that may be of interest to your oncology patients. We are pleased to announce the opening of the following clinical trial which may benefit some of your patients with prostate cancer.
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.
The primary objective for this study is to show superiority of treatment with DCVAC/PCa in addition to Standard of Care chemotherapy (docetaxel plus prednisone) over placebo in addition to Standard of Care chemotherapy (docetaxel plus prednisone) in men with mCRPC as measured by OS.
Any patients that feel like they qualify for this trial, or have questions regarding eligibility, please contact Hilda Agajanian at (562) 869-1201 to schedule an evaluation.
More about The Oncology Institute:
The Oncology Institute of Hope and Innovation is committed to providing superior, compassionate and state-of-the-
art medical care to our patients. We offer programs to help our patients and families cope with the challenges that are brought on by cancer and strive to optimize their quality of life. Comprehensive and realistic treatment goals are tailored to every person’s unique needs and decided upon in partnership with the patients and their families. We are dedicated to and excel in cancer prevention, diagnosis and education through our exceptional team of physicians, nurse practitioners, nurses, medical assistants and office staff.
Account Phone Number